NextCure stock: Avere merger backed by 820 million US dollars
Published on 11/12/2026 at 03:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMerger financing and shareholder vote
- NextCure said financing commitments for its proposed merger with Avere Therapeutics have risen to approximately 820 million US dollars.
- Stockholders are scheduled to vote on the transaction on December 9, while the merger remains subject to approval and other closing conditions.
- The Delaware Court of Chancery validated the company's July 2025 reverse stock split amendment on November 2.
NextCure said on November 10, 2026, that financing commitments supporting its proposed merger with Avere Therapeutics had risen to approximately 820 million US dollars. The company also reported results for the quarter ended September 30 and outlined the next steps for the transaction in a release carried by GlobeNewswire.
Financing backs proposed transaction
The financing consists of a previously announced 320 million US dollar private placement and an additional 500 million US dollar private placement. About 266 million US dollars of the latter is expected to be satisfied through the contribution and cancellation of Avere's outstanding convertible notes.
The proposed merger would combine NextCure with Avere, a privately held biotechnology company focused on oral therapies for IL-23-driven inflammatory diseases. If completed, the combined company is expected to operate as Avere and trade on Nasdaq under the ticker AVRX. Existing NextCure stockholders are expected to retain a minority ownership interest and receive contingent value rights tied to specified legacy assets.
Vote and legal milestones ahead
The registration statement on Form S-4 became effective on November 6, 2026, and NextCure began distributing definitive proxy materials. The company set November 3 as the record date and scheduled its special stockholder meeting for December 9 at 9:00 a.m. Eastern Time.
The merger still requires stockholder approval and other customary closing conditions. Separately, the Delaware Court of Chancery entered a final order on November 2 validating the amendment that implemented NextCure's July 2025 one-for-twelve reverse stock split and the shares issued in reliance on it.
NextCure's business and position
NextCure is a US clinical-stage biopharmaceutical company that has historically developed immunomedicines for cancer and other immune-related diseases through its FIND-IO discovery platform. Its current focus is managing legacy clinical and intellectual-property assets, pursuing opportunities to maximize those assets, fulfilling collaboration and licensing obligations, and advancing the Avere merger.
The company is positioned as a specialized development-stage biotechnology business rather than a commercial pharmaceutical producer. Its oncology activities compete for capital, partners and clinical relevance with larger companies such as Merck, Bristol Myers Squibb and Roche, while the proposed transaction would shift the operating focus toward Avere's oral IL-23 program.
NextCure at a glance
- Company: NextCure, Inc.
- ISIN: US65343E2072
- Ticker: NXTC
- Exchange: Nasdaq Global Select Market
- Headquarters: United States
- Business: Clinical-stage biopharmaceutical development
US equities remain the broader market backdrop for NextCure as investors assess merger financing and biotechnology risk. See the S&P 500 market environment.
More news and analyses on NextCure stock.
